Results 1 to 10 of about 53,590 (235)
Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo [PDF]
International Journal of Nanomedicine, 2016 Yi Zhou,1,2 Ruju Wang,1 Bing Chen,1 Dan Sun,3 Yong Hu,2 Peipei Xu1 1Department of Hematology, Drum Tower Hospital, School of Medicine, 2Institute of Materials Engineering and Collaborative Innovation Center of Chemistry for Life Sciences, College of ...
Zhou Y +5 more
doaj +3 more sources
Daunorubicin metabolism: estimation of daunorubicin reductase [PDF]
British Journal of Pharmacology, 1971 Summary Daunorubicin reductase, an enzyme ubiquitous in all mammalian tissues tested, converts daunorubicin, a cancer chemotherapeutic antibiotic, to daunorubicinol. A method for the estimation of daunorubicinol and daunorubicin reductase is described.
N R, Bachur, D H, Huffman
openaire +2 more sources
Pharmaceutics, 2022 Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia.
Guillaume Drevin +12 more
doaj +1 more source
Self‐association of daunorubicin [PDF]
FEBS Letters, 1974 with cytoxic and antimitotic activities. Presently it is used in the treatment of acute leukemia [ 1 ] . A considerable body of evidence has been accum- ulated which is in agreement with the existence of an intercalative complex with the DNA [2], which results in inhibition of both enzymatic RNA and DNA synthesis [3,4].
Barthelemy-Clavey, Véronique +3 more
openaire +2 more sources
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]
, 2015 Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant +49 more
core +6 more sources
Intrinsic and extrinsic apoptosis responses in leukaemia cells following daunorubicin treatment
BMC Cancer, 2021 Background Daunorubicin is used clinically in the treatment of myeloma, acute lymphatic and myelocytic leukaemia. The toxic lesions caused by daunorubicin induce various modes of cell death, including apoptosis.
Hussain Mubarak Al-Aamri +3 more
doaj +1 more source
Effects of Royal Jelly on Apoptosis and the Expression of Apoptotic Genes on Testicular Tissue in Male Balb/C Mice Treated with Daunorubicin [PDF]
Journal of Mazandaran University of Medical Sciences, 2023 Background and purpose: Daunorubicin is an effective drug in chemotherapy, but its clinical use is limited due to serious side effects. Royal jelly as a natural compound obtained from bees can be helpful in preventing the damage caused by daunorubicin ...
Mansour Safaei Pourzamani +4 more
doaj
Checkpoint Kinase 1 Activation Enhances Intestinal Epithelial Barrier Function via Regulation of Claudin-5 Expression. [PDF]
PLoS ONE, 2016 Several stressors are known to influence epithelial tight junction (TJ) integrity, but the association between DNA damage and TJ integrity remains unclear.
Akihiro Watari +3 more
doaj +1 more source
Artificial Cells, Nanomedicine, and Biotechnology, 2021 Brain glioma is the most common primary tumour of the central nervous system. Complete surgical removal of the brain glioma is virtually impossible. Chemotherapy is still an important treatment for brain glioma.
Hong-Jun Xie +6 more
doaj +1 more source
Journal of Pharmacological Sciences, 2005 The purpose of this study was to investigate the effects of daunorubicin on lipopolysaccharide (LPS)-stimulated inducible-type nitric oxide synthase (iNOS) expression in macrophages.
Fumiaki Saito +3 more
doaj +1 more source